Prolocor was
founded in 2020.

We are assembling a team of experienced scientists, clinicians, and industry leaders with experience in cardiovascular medicine, patient care, and diagnostics.

our team

Peter M. DiBattiste, MD, FACC, FAHA

Co-Founder & CEO

mobile minimised

Pete co-founded Prolocor and has served as the company’s CEO since 2020. Prior to founding Prolocor, he spent 14 years in a cardiovascular leadership role with Janssen R&D, mostly recently as Global Development Head of Cardiovascular and Head of Thrombosis Disease Area Stronghold. At Janssen, Pete oversaw numerous early and late-stage cardiovascular development programs, heading a group of 35 physicians and scientists specializing in cardiovascular drug development.

Earlier in his career, Pete was a member of cardiovascular research and development groups at AstraZeneca and Merck. Prior to joining the industry, Pete practiced medicine and was an Adjunct Professor at the University of Pennsylvania School of Medicine, The Lankenau Hospital, and Hahnemann University Hospital. He has authored more than 40 peer-reviewed publications in cardiovascular medicine.

Pete completed his Fellowship in Cardiology at the University of Pennsylvania. He holds an MD from Harvard Medical School.

David J. Schneider, MD, FACC, FAHA

Co-Founder & CSO

mobile minimised

David co-founded Prolocor and has served as the company’s CSO since 2020. David is a Professor of Medicine at the University of Vermont and has been at the University for the past 25+ years. Since 2013, David has also served as Director of the Cardiovascular Research Institute at the University of Vermont and Medical Director of Cardiovascular Services at the University of Vermont Health Network.

For many years, David has had an active research program focused on causal connections between diabetes and heart disease, and the role of platelets in the development and progression of atherosclerosis. He holds several patents including the use of a novel biomarker, FcɣRIIa, as a precision tool to guide care of patients with atherosclerotic vascular disease.

He has published more than 160 manuscripts and authored numerous chapters. David completed his Fellowship in Cardiology at Washington University in St. Louis. He holds an MD from the University of Cincinnati.

Ray Russo

Chief Commercial Officer

mobile minimised

Ray is a senior-level commercial executive with over 30 years of experience guiding cardiovascular drugs and devices from pre-launch through post-launch for large, medium, and startup biotech companies, including Schering-Plough, Merck, Prism Pharmaceuticals, and The Medicines Company.

Most recently, he served as Senior Vice President of Commercialization at Vero Biotech, successfully launching the first tankless inhaled nitric oxide system, Genosyl® DS. Earlier in his career, he led the launch of products like Integrilin®, Zetia®, Vytorin®, Nexterone®, and Kengreal®. Ray has led and participated in a broad array of capital raises and corporate exits, including the sale of Prism Pharmaceuticals to Baxter International and the sale of The Medicines Company's cardiovascular assets to Chiesi Pharma.

Ray has a BA in Economics and an MBA in Accounting from Rutgers University and he has sat on the Duke FUQUA School of Business Healthcare Sector Advisory Board and the Rutgers Undergraduate Advisory Council.

Edward L. Rosen

Board Director

mobile minimised

Ed has a 25-year background in life sciences as a leader of transformational growth, organizational build-out through commercialization, innovation and product development across Pharmaceutical, Device and Diagnostic businesses in key markets, channels and geographies.

Most recently, Ed served as Chief Strategy & Commercial Officer at Clinical Genomics. Prior to that, he served as Executive-in-Residence at Columbia University (Office of Technology Ventures) and President & CEO of Elucida Oncology, where he built the company through securing financing to advance its programs. Ed also spent nearly 20 years with Johnson & Johnson and Smith & Nephew in various positions, departing as Worldwide Vice President of Marketing at Mentor Worldwide, a Johnson & Johnson company.

Ed holds a BA (Hons) in Business Studies from the University of Lincoln in the UK.


Barbara A. Carlin, CPA, MBA

Consulting CFO

mobile minimised

Barb has a 25-year background in life sciences, leading finance and accounting management from start-ups to commercial-stage companies. In addition to leading Danforth’s Mid-Atlantic practice, Barb serves as a Consultant CFO for several of her clients.

Prior to joining Danforth, Barb served as CFO of Enterin, Chief Accounting Officer at Egalet Corporation (Zyla Life Sciences) where she helped build the infrastructure for an IPO and commercial launches. She also held finance leadership roles at SOBI, Topaz (acquired by Sanofi-Pasteur), Genaera and Vicuron (acquired by Pfizer). She began her career as an auditor at Deloitte.

Barb is a CPA and holds a BS in Accounting and MBA in Pharmaceutical & Healthcare Marketing from St. Joseph’s University in Philadelphia. Barb is on the Board of Directors of Life Sciences Pennsylvania and on the Board of Advisors for Life Science Cares Philadelphia.

Craig Sutton

Business Development

mobile minimised

Craig is a proven leader with deep experience in the medical device, diagnostics, and pharmaceutical sectors. He spent 37 years with J&J across various companies and in several key senior roles.

Most recently, Craig was Executive Director, Business Development and Alliance Management at Janssen Diagnostics. Prior to that, he was Executive Director, Business Development for Ortho Clinical Diagnostics, where he negotiated 8 license agreements with leading academic and commercial organizations with over $2 billion in projected revenue. Craig was also Executive Director, Metabolic Disease Business Unit.

Craig holds a BS in Biology and Economics from Bucknell University, and an MBA from the Lehigh University College of Business.